Cargando…

A cluster-randomized, non-inferiority trial comparing use of misoprostol for universal prophylaxis vs. secondary prevention of postpartum hemorrhage among community level births in Egypt

BACKGROUND: Previous community-based research shows that secondary prevention of postpartum hemorrhage (PPH) with misoprostol only given to women with above-average measured blood loss produces similar clinical outcomes compared to routine administration of misoprostol for prevention of PPH. Given t...

Descripción completa

Detalles Bibliográficos
Autores principales: Anger, Holly A., Dabash, Rasha, Hassanein, Nevine, Darwish, Emad, Ramadan, Mohamed Cherine, Nawar, Medhat, Charles, Dyanna, Breebaart, Miral, Winikoff, Beverly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245883/
https://www.ncbi.nlm.nih.gov/pubmed/32448257
http://dx.doi.org/10.1186/s12884-020-03008-5
_version_ 1783537838236631040
author Anger, Holly A.
Dabash, Rasha
Hassanein, Nevine
Darwish, Emad
Ramadan, Mohamed Cherine
Nawar, Medhat
Charles, Dyanna
Breebaart, Miral
Winikoff, Beverly
author_facet Anger, Holly A.
Dabash, Rasha
Hassanein, Nevine
Darwish, Emad
Ramadan, Mohamed Cherine
Nawar, Medhat
Charles, Dyanna
Breebaart, Miral
Winikoff, Beverly
author_sort Anger, Holly A.
collection PubMed
description BACKGROUND: Previous community-based research shows that secondary prevention of postpartum hemorrhage (PPH) with misoprostol only given to women with above-average measured blood loss produces similar clinical outcomes compared to routine administration of misoprostol for prevention of PPH. Given the difficulty of routinely measuring blood loss for all deliveries, more operational models of secondary prevention are needed. METHODS: This cluster-randomized, non-inferiority trial included women giving birth with nurse-midwives at home or in Primary Health Units (PHUs) in rural Egypt. Two PPH management approaches were compared: 1) 600mcg oral misoprostol given to all women after delivery (i.e. primary prevention, current standard of care); 2) 800mcg sublingual misoprostol given only to women with 350-500 ml postpartum blood loss estimated using an underpad (i.e. secondary prevention). The primary outcome was mean change in pre- and post-delivery hemoglobin. Secondary outcomes included hemoglobin ≥2 g/dL and other PPH interventions. RESULTS: Misoprostol was administered after delivery to 100% (1555/1555) and 10.7% (117/1099) of women in primary and secondary prevention clusters, respectively. The mean drop in pre- to post-delivery hemoglobin was 0.37 (SD: 0.91) and 0.45 (SD: 0.76) among women in primary and secondary prevention clusters, respectively (difference adjusted for clustering = 0.01, one-sided 95% CI: < 0.27, p = 0.535). There were no statistically significant differences in secondary outcomes, including hemoglobin drop ≥2 g/dL, PPH diagnosis, transfer to higher level, or other interventions. CONCLUSIONS: Misoprostol for secondary prevention of PPH is comparable to universal prophylaxis and can be implemented using local materials, such as underpads. TRIAL REGISTRATION: Clinicaltrials.gov NCT02226588, date of registration 27 August 2014.
format Online
Article
Text
id pubmed-7245883
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72458832020-06-01 A cluster-randomized, non-inferiority trial comparing use of misoprostol for universal prophylaxis vs. secondary prevention of postpartum hemorrhage among community level births in Egypt Anger, Holly A. Dabash, Rasha Hassanein, Nevine Darwish, Emad Ramadan, Mohamed Cherine Nawar, Medhat Charles, Dyanna Breebaart, Miral Winikoff, Beverly BMC Pregnancy Childbirth Research Article BACKGROUND: Previous community-based research shows that secondary prevention of postpartum hemorrhage (PPH) with misoprostol only given to women with above-average measured blood loss produces similar clinical outcomes compared to routine administration of misoprostol for prevention of PPH. Given the difficulty of routinely measuring blood loss for all deliveries, more operational models of secondary prevention are needed. METHODS: This cluster-randomized, non-inferiority trial included women giving birth with nurse-midwives at home or in Primary Health Units (PHUs) in rural Egypt. Two PPH management approaches were compared: 1) 600mcg oral misoprostol given to all women after delivery (i.e. primary prevention, current standard of care); 2) 800mcg sublingual misoprostol given only to women with 350-500 ml postpartum blood loss estimated using an underpad (i.e. secondary prevention). The primary outcome was mean change in pre- and post-delivery hemoglobin. Secondary outcomes included hemoglobin ≥2 g/dL and other PPH interventions. RESULTS: Misoprostol was administered after delivery to 100% (1555/1555) and 10.7% (117/1099) of women in primary and secondary prevention clusters, respectively. The mean drop in pre- to post-delivery hemoglobin was 0.37 (SD: 0.91) and 0.45 (SD: 0.76) among women in primary and secondary prevention clusters, respectively (difference adjusted for clustering = 0.01, one-sided 95% CI: < 0.27, p = 0.535). There were no statistically significant differences in secondary outcomes, including hemoglobin drop ≥2 g/dL, PPH diagnosis, transfer to higher level, or other interventions. CONCLUSIONS: Misoprostol for secondary prevention of PPH is comparable to universal prophylaxis and can be implemented using local materials, such as underpads. TRIAL REGISTRATION: Clinicaltrials.gov NCT02226588, date of registration 27 August 2014. BioMed Central 2020-05-24 /pmc/articles/PMC7245883/ /pubmed/32448257 http://dx.doi.org/10.1186/s12884-020-03008-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Anger, Holly A.
Dabash, Rasha
Hassanein, Nevine
Darwish, Emad
Ramadan, Mohamed Cherine
Nawar, Medhat
Charles, Dyanna
Breebaart, Miral
Winikoff, Beverly
A cluster-randomized, non-inferiority trial comparing use of misoprostol for universal prophylaxis vs. secondary prevention of postpartum hemorrhage among community level births in Egypt
title A cluster-randomized, non-inferiority trial comparing use of misoprostol for universal prophylaxis vs. secondary prevention of postpartum hemorrhage among community level births in Egypt
title_full A cluster-randomized, non-inferiority trial comparing use of misoprostol for universal prophylaxis vs. secondary prevention of postpartum hemorrhage among community level births in Egypt
title_fullStr A cluster-randomized, non-inferiority trial comparing use of misoprostol for universal prophylaxis vs. secondary prevention of postpartum hemorrhage among community level births in Egypt
title_full_unstemmed A cluster-randomized, non-inferiority trial comparing use of misoprostol for universal prophylaxis vs. secondary prevention of postpartum hemorrhage among community level births in Egypt
title_short A cluster-randomized, non-inferiority trial comparing use of misoprostol for universal prophylaxis vs. secondary prevention of postpartum hemorrhage among community level births in Egypt
title_sort cluster-randomized, non-inferiority trial comparing use of misoprostol for universal prophylaxis vs. secondary prevention of postpartum hemorrhage among community level births in egypt
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245883/
https://www.ncbi.nlm.nih.gov/pubmed/32448257
http://dx.doi.org/10.1186/s12884-020-03008-5
work_keys_str_mv AT angerhollya aclusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt
AT dabashrasha aclusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt
AT hassaneinnevine aclusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt
AT darwishemad aclusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt
AT ramadanmohamedcherine aclusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt
AT nawarmedhat aclusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt
AT charlesdyanna aclusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt
AT breebaartmiral aclusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt
AT winikoffbeverly aclusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt
AT angerhollya clusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt
AT dabashrasha clusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt
AT hassaneinnevine clusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt
AT darwishemad clusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt
AT ramadanmohamedcherine clusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt
AT nawarmedhat clusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt
AT charlesdyanna clusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt
AT breebaartmiral clusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt
AT winikoffbeverly clusterrandomizednoninferioritytrialcomparinguseofmisoprostolforuniversalprophylaxisvssecondarypreventionofpostpartumhemorrhageamongcommunitylevelbirthsinegypt